BioSpace News Archive

Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.

ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has entered into an exclusive global patent license agreement with Australia’s Walter and Eliza Hall Institute of Medical Research providing rights to CISH KO in the field of NK cells for the treatment of cancer.

Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company plans to participate in the Jefferies Virtual Healthcare Conference.

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 2:00 p.m. ET.

CollPlant, a regenerative and aesthetic medicine company, announced financial results for the first quarter ended March 31, 2021 and provided an update on the Company’s business developments.

Prizes include free cruises, tropical vacations, a VIP trip to Super Bowl LVI , courtesy of P&G, date nights and other activities that are #OneStepCloser following a vaccination

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis from the European Medicines Agency Committee for Orphan Medicinal Products.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company’s progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021.